Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study

BACKGROUND: Up to 20% of patients with chronic immune-mediated sensorimotor neuropathies (CIN) do not respond adequately to first-line therapies. However, studies on further treatment are scarce. METHODS: We analyzed retrospectively 200 CIN patients regarding disease characteristics and response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Motte, Jeremias, Fisse, Anna Lena, Köse, Nuray, Grüter, Thomas, Mork, Hannah, Athanasopoulos, Diamantis, Fels, Miriam, Otto, Susanne, Siglienti, Ines, Schneider-Gold, Christiane, Hellwig, Kerstin, Yoon, Min-Suk, Gold, Ralf, Pitarokoili, Kalliopi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940507/
https://www.ncbi.nlm.nih.gov/pubmed/33747132
http://dx.doi.org/10.1177/1756286421999631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940507/
https://www.ncbi.nlm.nih.gov/pubmed/33747132
http://dx.doi.org/10.1177/1756286421999631

Ejemplares similares